Abbott recently announced that they had been granted Breakthrough Device Designation by the FDA, which allows them to investigate the use of deep brain stimulation (DBS) in managing severe...
A study published in the Annals of Clinical and Translational Neurology found that psychotropic medication use in women may be associated with an increased risk of developing Parkinson’s disease...
Deep brain stimulation (DBS) — a neurosurgical approach for treatment-resistant neurological disorders — has become a revolutionary addition to the field of neuroscience and a beneficial tool for neurologists, neurosurgeons,...
In one decade, brand-name epilepsy drug prices have increased by 277%, according to a recent press release by the American Academy of Neurology. This review looked at data from Medicare patients...
Scientific Reports recently published a study that concluded transcutaneous vagus nerve stimulation (tVNS) altered cooperative behaviors in epilepsy patients. According to the Epilepsy Foundation,...
This week, Health Canada announced its approval of Albrioza (created by Amylyx Pharmaceuticals) for the treatment of ALS. It has been the only newly approved treatment for ALS since 2018. The drug is...
Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant drugs that treat depression and other mental health conditions by inhibiting the reabsorption of serotonin by neurons in the brain.
According to the National...
